Peritoneal carcinomatosis in non-small-cell lung cancer: retrospective multicentric analysis and literature review

Maria Ida Abbate; Diego Luigi Cortinovis; Marcello Tiseo; Tiziana Vavalà; Giulio Cerea; Luca Toschi; Stefania Canova; Francesca Colonese; Paolo Bidoli

doi:10.2217/fon-2018-0469

Peritoneal carcinomatosis in non-small-cell lung cancer: retrospective multicentric analysis and literature review

Maria Ida Abbate, Diego Luigi Cortinovis, Marcello Tiseo, Tiziana Vavalà, Giulio Cerea, Luca Toschi, Stefania Canova, Francesca Colonese, Paolo Bidoli

Istituto Clinico Humanitas

Research output: Contribution to journal › Review article › peer-review

Abstract

AIM: We investigated outcomes in patients with advanced non-small-cell lung cancer (NSCLC) and peritoneal involvement.

PATIENTS & METHODS: NSCLC patients with peritoneal carcinomatosis (PC) were included. We evaluated mOS1 (overall survival [OS] from NSCLC diagnosis) and mOS2 (OS from diagnosis of PC).

RESULTS: In total, 60 NSCLC patients were diagnosed with PC, 12 (20%) patients had a diagnosis of NSCLC and synchronous PC with a median OS of 9 months. Smokers had a shorter mOS1 and mOS2 compared with never-smokers; EGFR-mutated patients on tyrosine kinase inhibitors had longer mOS1 and mOS2 than EGFR wild-type patients.

CONCLUSION: Metachronous PC is correlated to a short survival, irrespective of treatment line. Never-smokers and EGFR-mutated patients had improved mOS1 and mOS2 when compared with smokers and EGFR wild-type population.

Original language	English
Pages (from-to)	989-994
Number of pages	6
Journal	Future oncology (London, England)
Volume	15
Issue number	9
DOIs	https://doi.org/10.2217/fon-2018-0469
Publication status	Published - Mar 2019

Keywords

Adult
Age Factors
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols/pharmacology
Carcinoma, Non-Small-Cell Lung/drug therapy
ErbB Receptors/antagonists & inhibitors
Female
Humans
Lung Neoplasms/drug therapy
Male
Middle Aged
Mutation
Non-Smokers/statistics & numerical data
Peritoneal Neoplasms/drug therapy
Progression-Free Survival
Protein Kinase Inhibitors/pharmacology
Retrospective Studies
Sex Factors
Smokers/statistics & numerical data

Access to Document

10.2217/fon-2018-0469

Cite this

@article{dd7df5bead34404386e413a7008b7efc,

title = "Peritoneal carcinomatosis in non-small-cell lung cancer: retrospective multicentric analysis and literature review",

abstract = "AIM: We investigated outcomes in patients with advanced non-small-cell lung cancer (NSCLC) and peritoneal involvement.PATIENTS & METHODS: NSCLC patients with peritoneal carcinomatosis (PC) were included. We evaluated mOS1 (overall survival [OS] from NSCLC diagnosis) and mOS2 (OS from diagnosis of PC).RESULTS: In total, 60 NSCLC patients were diagnosed with PC, 12 (20%) patients had a diagnosis of NSCLC and synchronous PC with a median OS of 9 months. Smokers had a shorter mOS1 and mOS2 compared with never-smokers; EGFR-mutated patients on tyrosine kinase inhibitors had longer mOS1 and mOS2 than EGFR wild-type patients.CONCLUSION: Metachronous PC is correlated to a short survival, irrespective of treatment line. Never-smokers and EGFR-mutated patients had improved mOS1 and mOS2 when compared with smokers and EGFR wild-type population.",

keywords = "Adult, Age Factors, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols/pharmacology, Carcinoma, Non-Small-Cell Lung/drug therapy, ErbB Receptors/antagonists & inhibitors, Female, Humans, Lung Neoplasms/drug therapy, Male, Middle Aged, Mutation, Non-Smokers/statistics & numerical data, Peritoneal Neoplasms/drug therapy, Progression-Free Survival, Protein Kinase Inhibitors/pharmacology, Retrospective Studies, Sex Factors, Smokers/statistics & numerical data",

author = "Abbate, {Maria Ida} and Cortinovis, {Diego Luigi} and Marcello Tiseo and Tiziana Vaval{\`a} and Giulio Cerea and Luca Toschi and Stefania Canova and Francesca Colonese and Paolo Bidoli",

year = "2019",

month = mar,

doi = "10.2217/fon-2018-0469",

language = "English",

volume = "15",

pages = "989--994",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Future Medicine Ltd.",

number = "9",

}

TY - JOUR

T1 - Peritoneal carcinomatosis in non-small-cell lung cancer

T2 - retrospective multicentric analysis and literature review

AU - Abbate, Maria Ida

AU - Cortinovis, Diego Luigi

AU - Tiseo, Marcello

AU - Vavalà, Tiziana

AU - Cerea, Giulio

AU - Toschi, Luca

AU - Canova, Stefania

AU - Colonese, Francesca

AU - Bidoli, Paolo

PY - 2019/3

Y1 - 2019/3

N2 - AIM: We investigated outcomes in patients with advanced non-small-cell lung cancer (NSCLC) and peritoneal involvement.PATIENTS & METHODS: NSCLC patients with peritoneal carcinomatosis (PC) were included. We evaluated mOS1 (overall survival [OS] from NSCLC diagnosis) and mOS2 (OS from diagnosis of PC).RESULTS: In total, 60 NSCLC patients were diagnosed with PC, 12 (20%) patients had a diagnosis of NSCLC and synchronous PC with a median OS of 9 months. Smokers had a shorter mOS1 and mOS2 compared with never-smokers; EGFR-mutated patients on tyrosine kinase inhibitors had longer mOS1 and mOS2 than EGFR wild-type patients.CONCLUSION: Metachronous PC is correlated to a short survival, irrespective of treatment line. Never-smokers and EGFR-mutated patients had improved mOS1 and mOS2 when compared with smokers and EGFR wild-type population.

AB - AIM: We investigated outcomes in patients with advanced non-small-cell lung cancer (NSCLC) and peritoneal involvement.PATIENTS & METHODS: NSCLC patients with peritoneal carcinomatosis (PC) were included. We evaluated mOS1 (overall survival [OS] from NSCLC diagnosis) and mOS2 (OS from diagnosis of PC).RESULTS: In total, 60 NSCLC patients were diagnosed with PC, 12 (20%) patients had a diagnosis of NSCLC and synchronous PC with a median OS of 9 months. Smokers had a shorter mOS1 and mOS2 compared with never-smokers; EGFR-mutated patients on tyrosine kinase inhibitors had longer mOS1 and mOS2 than EGFR wild-type patients.CONCLUSION: Metachronous PC is correlated to a short survival, irrespective of treatment line. Never-smokers and EGFR-mutated patients had improved mOS1 and mOS2 when compared with smokers and EGFR wild-type population.

KW - Adult

KW - Age Factors

KW - Aged

KW - Aged, 80 and over

KW - Antineoplastic Combined Chemotherapy Protocols/pharmacology

KW - Carcinoma, Non-Small-Cell Lung/drug therapy

KW - ErbB Receptors/antagonists & inhibitors

KW - Female

KW - Humans

KW - Lung Neoplasms/drug therapy

KW - Male

KW - Middle Aged

KW - Mutation

KW - Non-Smokers/statistics & numerical data

KW - Peritoneal Neoplasms/drug therapy

KW - Progression-Free Survival

KW - Protein Kinase Inhibitors/pharmacology

KW - Retrospective Studies

KW - Sex Factors

KW - Smokers/statistics & numerical data

U2 - 10.2217/fon-2018-0469

DO - 10.2217/fon-2018-0469

M3 - Review article

C2 - 30681378

SN - 1479-6694

VL - 15

SP - 989

EP - 994

JO - Future Oncology

JF - Future Oncology

IS - 9

ER -

Peritoneal carcinomatosis in non-small-cell lung cancer: retrospective multicentric analysis and literature review

Abstract

Keywords

Access to Document

Fingerprint

Cite this